Brian Cahill's Insider Trades & SAST Disclosures
Brian Cahill's most recent trade in Eagle Pharmaceuticals Inc was a trade of 3,800 Common Stock done . Disclosure was reported to the exchange on Feb. 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Brian Cahill.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | Brian Cahill | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 3,800 | 49,547 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Cahill Brian | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.44 per share. | 27 Feb 2024 | 1,589 | 47,958 (0%) | 0% | 6.4 | 10,233 | Common Stock |
| Eagle Pharmaceuticals Inc | Cahill Brian | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.85 per share. | 02 Feb 2024 | 934 | 45,747 (0%) | 0% | 5.9 | 5,464 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. | 05 Jan 2024 | 735 | 46,681 (0%) | 0% | 5.1 | 3,771 | Common Stock |
| Eagle Pharmaceuticals Inc | Cahill Brian | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 18 Dec 2023 | 452 | 47,416 (0%) | 0% | 4.8 | 2,152 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 18,500 | 47,868 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.00 per share. | 28 Feb 2023 | 718 | 29,368 (0%) | 0% | 28 | 20,104 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.09 per share. | 02 Feb 2023 | 785 | 30,086 (0%) | 0% | 34.1 | 26,761 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.21 per share. | 30 Jan 2023 | 601 | 30,871 (0%) | 0% | 33.2 | 19,959 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.26 per share. | 05 Jan 2023 | 734 | 31,472 (0%) | 0% | 29.3 | 21,477 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.03 per share. | 19 Dec 2022 | 461 | 32,206 (0%) | 0% | 30.0 | 13,844 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 8,000 | 32,667 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.03 per share. | 02 Feb 2022 | 805 | 24,667 (0%) | 0% | 45.0 | 36,249 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.94 per share. | 31 Jan 2022 | 626 | 25,472 (0%) | 0% | 45.9 | 28,758 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.63 per share. | 07 Jan 2022 | 263 | 26,098 (0%) | 0% | 50.6 | 13,316 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.69 per share. | 05 Jan 2022 | 738 | 26,361 (0%) | 0% | 50.7 | 37,409 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 8,900 | 27,566 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.67 per share. | 29 Jan 2021 | 637 | 18,666 (0%) | 0% | 46.7 | 29,729 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.97 per share. | 07 Jan 2021 | 237 | 14,303 (0%) | 0% | 51.0 | 12,080 | Common Stock |
| Eagle Pharmaceuticals Inc | Brian Cahill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.02 per share. | 05 Jan 2021 | 746 | 14,540 (0%) | 0% | 50.0 | 37,315 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges